Efficacy and safety of tislelizumab in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis

Abstract Background Tislelizumab, a PD-1-targeting monoclonal antibody, can potentially treat advanced esophageal squamous cell carcinoma (ESCC). Using pooled clinical data, this study evaluates Tislelizumab's efficacy and safety in advanced ESCC. Methods This review followed PRISMA guidelines, with...

詳細記述

書誌詳細

主要な著者:	Eric Ricardo Yonatan, Surya Sinaga Immanuel, Erlangga Saputra Arifin, Louis Fabio Jonathan Jusni, Riki Tenggara, Mario Steffanus, Delia Anastasia Tirtadjaja
フォーマット:	Artigo
言語:	Inglês
出版事項:	SpringerOpen 2025-08-01
シリーズ:	Journal of the Egyptian National Cancer Institute
主題:	Tislelizumab Advanced esophageal squamous cell carcinoma Survival analysis Treatment outcome Adverse events
オンライン･アクセス:	https://doi.org/10.1186/s43046-025-00315-w
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!